OOIR: Observatory of International Research

Papers

(The H4-Index of EMBO Molecular Medicine is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
IL‐27 produced during acute malaria infection regulates Plasmodium‐specific memory CD4⁺ T cells	321
Tumor‐associated macrophages‐educated reparative macrophages promote diabetic wound healing	243
Liquid biopsy: blood‐based analyses of circulating cell‐free DNA in xenografts	203
Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer	138
Nanobodies dismantle post‐pyroptotic ASC specks and counteract inflammation in vivo	128
Dependence receptors: new targets for cancer therapy	116
miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC	110
Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders	108
A high‐resolution 3D atlas of the spectrum of tuberculous and COVID ‐19 lung lesions	100
Pdia4 regulates β‐cell pathogenesis in diabetes: molecular mechanism and targeted therapy	97
Brain p3‐Alcβ peptide restores neuronal viability impaired by Alzheimer's amyloid β‐peptide	94
Nanobody‐mediated complement activation to kill HIV‐infected cells	85
Targeting CD301⁺ macrophages inhibits endometrial fibrosis and improves pregnancy outcome	78
Adaptively evolved human oral actinomyces‐sourced defensins show therapeutic potential	77
PI3Kα targeting, nipping pancreatic cancer evolution in the bud	65
Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis	62
Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics	61
Lifting the iron curtain of vision	59
Whole‐brain microscopy reveals distinct temporal and spatial efficacy of anti‐Aβ therapies	58
SARS‐CoV ‐2 spike protein enhances MAP4K3 / GLK ‐induced ACE2 stability	58
Alleviation of a polyglucosan storage disorder by enhancement of autophagic glycogen catabolism	54
Immunological barriers to immunotherapy in primary and metastatic breast cancer	53
FAM3C/ILEI protein is elevated in psoriatic lesions and triggers psoriasiform hyperproliferation in mice	53
Proteolytically generated soluble Tweak Receptor Fn14 is a blood biomarker for γ‐secretase activity	50
M‐CSF directs myeloid and NK cell differentiation to protect from CMV after hematopoietic cell transplantation	50

Conformational change of adenine nucleotide translocase‐1 mediates cisplatin resistance induced by EBV‐LMP1	49
Actionable loss of SLF2 drives B‐cell lymphomagenesis and impairs the DNA damage response	49
THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer	47
The HSP40 chaperone Ydj1 drives amyloid beta 42 toxicity	46
Metabolic switch from fatty acid oxidation to glycolysis in knock‐in mouse model of Barth syndrome	46
Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency	44
Trichothiodystrophy‐associated MPLKIP maintains DBR1 levels for proper lariat debranching and ectodermal differentiation	44
iPSC‐based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation	44
Concurrent targeting of glycolysis in bacteria and host cell inflammation in septic arthritis	43
Intercepting IRE1 kinase‐FMRP signaling prevents atherosclerosis progression	43
FIBCD1 is an endocytic GAG receptor associated with a novel neurodevelopmental disorder	43
In situ mass spectrometry imaging reveals heterogeneous glycogen stores in human normal and cancerous tissues	43
Oxidized LDL‐dependent pathway as new pathogenic trigger in arrhythmogenic cardiomyopathy	43
Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19	42
miR ‐181a/b downregulation: a mutation‐independent therapeutic approach for inherited retinal diseases	42
Involvement of casein kinase 1 epsilon/delta (Csnk1e/d) in the pathogenesis of familial Parkinson's disease caused by CHCHD2	40